Probiotics and pidotimod show inconsistent evidence for managing intestinal and immune health in HIVEvaluating the Role of Probiotics and Pidotimod in Managing HIV Health

This narrative mini-review explores the potential of probiotics and pidotimod to influence the intestinal ecosystem, barrier function, and innate and mucosal immune responses in patients with HIV receiving effective antiretroviral therapy. The review synthesizes current literature to evaluate these interventions as potential adjuncts for managing immune status.

Regarding probiotics, the authors note that evidence is heterogeneous across various strains, formulations, doses, treatment durations, and ART status. This variability makes it difficult to establish a consistent clinical effect for the probiotic class in this population. For pidotimod, the review notes that while immunological and clinical signals have been observed in small adult studies for community-acquired pneumonia and COVID-19, HIV-specific evidence is currently limited to a pilot study.

The authors highlight significant limitations, specifically the heterogeneous evidence for probiotics and the limited HIV-specific data for pidotimod. These findings do not establish a generalized probiotic class effect or establish pidotimod as a therapy for residual immune activation in treated HIV. The review suggests that while these findings support further hypothesis-driven investigation, the current evidence is insufficient to support routine clinical application for these specific indications.